Consistent with this pathological progression of NAFLD/NASH, a growing body of evidence showed that the patients with NAFLD/NASH have elevated concentrations of IL-6, TNF-α, and MCP-1 [42, 43]. This evidence concerns the gene CCL2 and metabolic dysfunction-associated steatotic liver disease.